Abstract
This article gives a summary of several studies presented at the San Antonio Breast Cancer Symposium in 2018. In specific, the biomarker analysis of the ‘IMpassion130’ trial, the effects of CDK4/6 inhibitors on T-cells and tumor immunogenicity, adjuvant chemotherapy in older patients, the prognostic relevance of achieving a pathologic complete response after neoadjuvant therapy, the quality of life analysis of the ‘TAILORx’ trial, the prognostic impact of detecting bone marrow tumor cells at the time of primary resection and b-cell lymphoma 2 as a new possible therapeutic target in luminal breast cancer, are discussed.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call